Thursday, September 9, 2021 Daily Archives

Optimizing the Accuracy of Biopharma Flow-Measurement Applications With the BioProTT™ FlowMeasurement System

by

The BioProTTTM FlowMeasurement System for the non-invasive measurement of volumetric flows within flexible tubing systems is suitable for both industrial and laboratory applications. It always consists of an evaluation device and a sensor. To ensure the highest possible accuracy, each sensor is adjusted and calibrated according to certain parameters based on the customer’s application. In addition, there are also external factors that impact the accuracy. This document will highlight and explain these factors so that system integrators and operators are…

September 9, 2021

Moderna to develop mRNA therapeutic for ultra-rare disease

by

Moderna and non-profit firm Institute for Life Changing Medicines have partnered to develop mRNA-3351 for Crigler-Najjar Syndrome Type 1. Under the terms of the agreement, messenger RNA (mRNA) biopharma company Moderna will licence mRNA-3351 to the Institute for Life Changing Medicines (ILCM) with no upfront fees or downstream payments. ILCM will be responsible for clinically developing mRNA-3351 and anticipates clinical studies to begin in 2022. mRNA-3351 uses the same lipid nano particle (LNP) formulation as the firm’s antibody against chikungunya virus…

September 9, 2021

Thermo Fisher doubling single-use capacity through $100m Nashville plant

by

Thermo Fisher will hire 1,400 staff at the facility in Nashville, Tennessee, which is expected to feed biomanufacturing’s continued demand for single-use technologies. Bioprocess vendor Thermo Fisher Scientific unveiled plans yesterday to bolster its manufacturing network for single-use technology (SUT) products through the construction of a facility in Wilson County, Tennessee. “The new site will be Thermo Fisher’s largest designated SUT manufacturing facility and will help more than double Thermo Fisher’s network manufacturing capacity to support its biopharma customers,†a…

September 9, 2021

Sanofi bolsters stem cell biz with $1.9bn Kadmon buy

by

Sanofi will grow its regenerative medicine  business through the acquisition of Kadmon, adding FDA-approved stem cell transplant Rezurock to its portfolio.   The deal sees French pharma giant Sanofi pay Kadmon Holdings $9.50 per share in cash, equalling a total equity value of approximately $1.9 billion. “The acquisition supports continued growth of our transplant business and adds a complementary offering that expands Sanofi’s portfolio and leverages the company’s expertise in stem cell transplant,†a spokesperson for Sanofi told BioProcess Insider.…

September 9, 2021